Neurocrine biosciences presents findings contributing to the growing body of evidence on the impact of high-dose glucocorticoids on clinical outcomes in congenital adrenal hyperplasia

Most studies meeting the literature review criteria found that a higher glucocorticoid dose was statistically significantly associated with adverse clinical outcomes findings presented at the 2025 international society for pharmacoeconomics and outcomes research annual meeting san diego , may 14, 2025 /prnewswire/ -- neurocrine biosciences, inc.  (nasdaq: nbix) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. this study was presented at the 2025 international society for pharmacoeconomics and outcomes research (ispor) annual meeting in montreal, canada.
NBIX Ratings Summary
NBIX Quant Ranking